Selecta, JDRF and Sanofi Extend Collaboration to Develop a Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes
![](/46/pdcnewsitem/03/37/64/pUwPhW83tEaN6NZ.gif)
Selecta Biosciences and JDRF have extended their joint research collaboration and attracted Sanofi as a partner in support of their programme to develop a synthetic vaccine particle (SVP) immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. This collaborative research programme is aimed at accelerating the advancement of an SVP immunotherapy designed to reset the immune system and restore tolerance to substances (antigens) that cause the immune attacks on insulin-producing cells in the pancreas. Selecta’s proprietary tolerogenic SVP products show potential to re-educate the immune system to stop or suppress pro-inflammatory responses against a specific antigen, thereby halting the undesirable immune reaction without causing harmful global immune suppression common with general immune system modulating drugs.
As part of their collaboration, JDRF and Sanofi are co-financing the programme with the aim of advancing the SVP product candidate to the clinic. This next phase of the SVP development programme has been structured as a grant award to Selecta to test up to four antigens that may succeed in stopping the autoimmune response that destroys beta cells.
“This agreement with JDRF and Sanofi is a next step in our research to advance SVP in type 1 diabetes,” said Werner Cautreels, PhD, President and CEO at Selecta. “Selecta’s proprietary SVP platform has broad applications in tolerance and Selecta is now active in multiple areas of high medical need, including undesired immune responses to biological drugs, and gene therapy, allergies, and autoimmune diseases.”
“JDRF has a strategic research plan designed to deliver a sustained stream of new, life-changing therapies. Our support of Selecta is one part of our restoration research programme whose ultimate goal is to restore a person’s normal functioning — in short, a biological cure for type 1 diabetes. We see great potential in antigen-specific immunotherapies, like SVP, in helping us meet that goal, and have seen tremendous progress since we started our collaboration with Selecta,” said Julia Greenstein, PhD, Vice President of Discovery Research at JDRF. “Bringing Sanofi on board is a key milestone towards accelerating the translation of this new class of therapies.”
In June, 2011, JDRF and Selecta announced a research collaboration to support Selecta's development of antigen-specific tolerance products, which contributed to the screening of tolerance inducing immunomodulators and nanoparticles for applications in autoimmune diseases. This work serves as the basis for the new partnership with Sanofi.
In November, 2012, Sanofi and Selecta announced that they had formed a strategic global collaboration to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies. Under the agreement, Sanofi obtained an exclusive licence to develop an immunotherapy designed to abate acute immune responses against a life threatening food allergen and an option to develop two additional candidate immunotherapies for allergies each to a specific food or aeroallergen.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance